These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31670988)

  • 1. Opicapone for the treatment of Parkinson's disease: an update.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2019 Dec; 20(18):2201-2207. PubMed ID: 31670988
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
    Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
    Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
    Harrison-Jones G; Marston XL; Morgante F; Chaudhuri KR; Castilla-Fernández G; Di Foggia V
    Eur J Neurol; 2023 Oct; 30(10):3132-3141. PubMed ID: 37489574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opicapone (Ongentys) - a COMT inhibitor for Parkinson's disease.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):3-5. PubMed ID: 33646998
    [No Abstract]   [Full Text] [Related]  

  • 9. Opicapone for the treatment of Parkinson's disease.
    Rodrigues FB; Ferreira JJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opicapone for Parkinson's disease: clinical evidence and future perspectives.
    Leung C; Rascol O; Fabbri M
    Neurodegener Dis Manag; 2021 Jun; 11(3):193-206. PubMed ID: 33745288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entacapone in the management of Parkinson's disease.
    Henchcliffe C; Waters C
    Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
    Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
    Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
    Annus Á; Vécsei L
    Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.